Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 721 to 735 of 1688 results for carers

  1. Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]

    Awaiting development [GID-TA11365] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Ensitrelvir for treating COVID-19 [ID6231]

    Awaiting development [GID-TA11224] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]

    Awaiting development [GID-TA11137] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]

    Awaiting development [GID-TA11326] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226]

    Awaiting development [GID-TA11231] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Electrically stimulated intravesical therapy for interstitial cystitis or overactive bladder in adults

    In development [GID-IPG10362] Expected publication date: 09 January 2025

    Interventional procedures guidance
    In development

  7. Quality standards: process guide (PMG43)

    This guide describes the process NICE uses to develop NICE quality standards

  8. Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]

    In development [GID-TA11160] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Upadacitinib for treating giant cell arteritis [ID6299]

    Awaiting development [GID-TA11330] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy [ID6354]

    Awaiting development [GID-TA11415] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099]

    Awaiting development [GID-TA10972] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]

    Awaiting development [GID-TA11300] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]

    Awaiting development [GID-TA11341] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]

    Awaiting development [GID-TA11491] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]

    Awaiting development [GID-TA11494] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development